




## Beijing, China



### SITE HEAD

**Shin-Jee Chan**  
*Senior Director,  
Lab Operations*


**Our Beijing, China laboratory provides central lab, genomics, bioanalysis, and vaccine services.** With a staff of 400 and over 20 years of demonstrated expertise in providing clinical trial services, we support local and global vaccine trials.

### Lab overview

- Provide full central lab services, from kit building to data management
- Conducting vaccine trials since 2018
- Joined CEPI's global network of COVID-19 vaccine testing labs in November 2021
- 1200 sqm BSL 2 labs (Molecular, Immunoassay, Cell Culture, Specimen Management)
- Operate under CAP, GCLP, and EHS standards
- Experienced in hosting NMPA (National Medical Products Administration) inspections
- Experienced in regulatory requirement, e.g., reagent/virus/sample import permit application

### Key lab equipment

- Luminex 200
- SpectraMax 384
- SpectraMax i3x
- SpectraMax L
- CTL Immunospot S6 Ultimate
- Tecan Automated Workstation
- AutoLiPA
- QIASymphony



## Key abilities

- ELISA
- Multiplex assay
- Virus neutralization assay
- Elispot
- Line probe assay

## Vaccines

- HPV
- RSV
- COVID-19

## Team

- Site Head: Shin-Jee Chan, Senior Director, Lab Operations
- 30 Technical staff with other supporting staff, like Specimen Management and Quality Assurance

## About Nexelis, a Q<sup>2</sup> Solutions Company

With unrivaled expertise in immunology, five operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q<sup>2</sup> Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic, and oncologic fields. Our versatile team of scientists, working with state-of-the-art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

## Contact us

---

**Website:** [www.nexelis.com](http://www.nexelis.com)